Background: The recent spread of positron emission tomography-computed tomography (PET/CT) poses extremity dosimetry challenges. The question arose whether the radiation dose measured by the ring thermoluminescent dosimeter usually worn on the proximal phalanx (P1) of the index finger measures doses that are representative of the true doses received by the upper extremities of the operators. A prospective individual dosimetry study was performed in which the personal equivalent dose Hp (0.07) received during a specific 2-[(18)F]fluoro-2-deoxy-D-glucose ((18)F-FDG) manual dose-dispensing procedure was measured in a paired design by two operational personal electronic dosimeters fitted on the palm side of the index finger, namely in the P1 and distal phalanx (P3) positions. The study participants were ten nuclear medicine technologists working in two nuclear medicine departments. The personal equivalent radiation doses received by the palm side of the proximal phalanx of the index finger [Hp (0.07)P1] and that received by the distal phalanx [Hp (0.07)P3] were compared.
Results: The median Hp (0.07)P3/Hp (0.07)P1 ratio per participant varied between 1.0 and 2.5 (based on 23 to 31 measurements per participant). The 271 paired measurements revealed a crude Hp (0.07)P3/Hp (0.07)P1 ratio of 1.67, significantly different from 1 (p = 0.0004, 95 % CI [1.35-2.07]). When adjusted on participant's gender and mother vial activity, the ratio was similar (1.53, p = 0.003, 95 % CI [1.22-1.92]).
Conclusions: The study demonstrated a significant disparity that may exist between the radiation doses measured in the P1 and P3 positions of operators during (18)F-FDG manipulation. These findings emphasize the importance of performing workplace dosimetry studies adapted to each radiopharmaceutical and manipulation thereof, aiming to guarantee optimal workers' dosimetry monitoring schemes.
Trial Registration: Hospital Nursing and Paramedical Research Program (PHRIP, 2011-2013) from the French Ministry of Health (DGOS), http://social-sante.gouv.fr/IMG/pdf/Resultats_PHRIP_2011.pdf.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975735 | PMC |
http://dx.doi.org/10.1186/s40658-016-0152-5 | DOI Listing |
Alzheimers Dement
December 2024
Indiana University School of Medicine, Indianapolis, IN, USA.
Background: The goal of the TREAT-AD Center is to enable drug discovery by developing assays and providing tool compounds for novel and emerging targets. The role of microglia in neuroinflammation has been implicated in the pathogenesis of Alzheimer's disease (AD). Genome-wide association studies, whole genome sequencing, and gene-expression network analyses comparing normal to AD brain have identified risk and protective variants in genes essential to microglial function.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Keck School of Medicine at University of Southern California, Los Angeles, CA, USA.
Background: ABCA1-mediated cholesterol transport is a central feature in many lipid- dependent diseases including APOE4-associated Alzheimer's disease and atherosclerosis-CVD. ABCA1 upregulation of RNA transcription by nuclear factors (LXR, RXR) have been associated with liver side-effects because of the common promotor element for ABCA1 and Fatty Acid Synthase. The ABCA1 agonist CS6253, derived from the C-terminal of apoE was designed to stabilize and enhance ABCA1 function, thereby providing a safe alternative to transcriptional upregulation.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.
Background: Amyloid imaging biomarkers serve an increasingly important role in diagnosing Alzheimer's disease and determining eligibility for treatment with new disease-modifying therapies. Yet, psychological and behavioral reactions to receiving a biomarker informed diagnosis remain relatively unstudied, especially in diverse and underserved populations where the burden of disease is high and resources for support are often insufficient. We developed the Patient And family member Reactions to biomarker-informed ADRD DiagnosEs (PARADE) Study to address two key gaps in our understanding: 1) the range and trajectory of psychological and behavioral responses to a biomarker informed diagnosis and 2) the support needs of these individuals and their families.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Brain Institute of Rio Grande do Sul - Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
Background: Although cognitive decline is a trait related to aging, some individuals are resilient to the aging process, defined as SuperAgers. Studying the neural underpinnings of SuperAgers may improve the understanding of AD pathology. In this study, our aim was to analyze amyloid and neurodegeneration imaging biomarkers in SuperAgers.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Alzheimer's Disease Neuroimaging Initiative, http://adni.loni.usc.edu/, CA, USA.
Background: Amyloid and tau pathologies are the hallmarks of Alzheimer's disease (AD). Previous research indicated notable connections between financial capacity and AD biomarkers. Here, we aimed to understand whether financial capacity is affected by the cerebral accumulation of tau and amyloid.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!